Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Nexalin Technology Inc. (NXL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: NXL (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 45.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.49M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 4.05 | 52 Weeks Range 0.59 - 4.49 | Updated Date 07/5/2025 |
52 Weeks Range 0.59 - 4.49 | Updated Date 07/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4903.63% |
Management Effectiveness
Return on Assets (TTM) -189.48% | Return on Equity (TTM) -367.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13548559 | Price to Sales(TTM) 125.83 |
Enterprise Value 13548559 | Price to Sales(TTM) 125.83 | ||
Enterprise Value to Revenue 103.37 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 17177900 | Shares Floating 14715129 |
Shares Outstanding 17177900 | Shares Floating 14715129 | ||
Percent Insiders 14.34 | Percent Institutions 2.28 |
Upturn AI SWOT
Nexalin Technology Inc.
Company Overview
History and Background
Nexalin Technology, Inc. is a medical device company focusing on developing and commercializing neurostimulation devices. Founded in 2010, it has focused on creating non-invasive technologies to address mental health issues like anxiety and depression. The company has evolved from initial research and development to clinical trials and seeking regulatory approvals.
Core Business Areas
- Neurostimulation Devices: Nexalin develops and markets neurostimulation devices designed to treat anxiety, depression, and insomnia. Their core product is a non-invasive brain stimulation technology.
Leadership and Structure
The company is led by a team of executives with experience in medical device development and commercialization. The organizational structure includes departments for research and development, clinical operations, sales, and marketing.
Top Products and Market Share
Key Offerings
- Gen-1 and Gen-2 Nexalin Systems: These are non-invasive neurostimulation devices that deliver targeted stimulation to the brain. Market share is small as it is a newer market and product. Competitors include transcranial magnetic stimulation (TMS) devices from companies such as Neuronetics (STIM) and BrainsWay (BWAY).
Market Dynamics
Industry Overview
The neurostimulation market is growing, driven by increasing prevalence of mental health disorders and demand for non-pharmacological treatments. Growth rate is expected to continue at around 7.8% annually with a projected market size of $11 billion USD by 2032. The market includes various technologies like TMS, vagus nerve stimulation (VNS), and transcranial direct current stimulation (tDCS).
Positioning
Nexalin is positioned as a developer of novel neurostimulation technology offering a potentially more convenient and less invasive alternative to existing treatments.
Total Addressable Market (TAM)
The TAM for neurostimulation devices targeting mental health is estimated to be several billion dollars, growing with the increasing awareness and acceptance of non-pharmacological interventions. Nexalin is positioned to capture a share of this market with its proprietary technology but is a smaller player currently.
Upturn SWOT Analysis
Strengths
- Proprietary neurostimulation technology
- Non-invasive treatment approach
- Potential for fewer side effects compared to medication
Weaknesses
- Limited clinical data compared to established treatments
- Small market share
- Dependence on regulatory approvals
- High cash burn and limited funding.
Opportunities
- Expansion into new indications (e.g., PTSD, addiction)
- Partnerships with healthcare providers and research institutions
- Increased awareness and acceptance of neurostimulation therapies
Threats
- Competition from established neurostimulation companies
- Regulatory hurdles and delays
- Uncertainty regarding long-term efficacy and safety
- Reimbursement challenges from insurers.
Competitors and Market Share
Key Competitors
- Neuronetics (STIM)
- BrainsWay (BWAY)
- LivaNova PLC (LIVN)
Competitive Landscape
Nexalin faces significant competition from larger, more established companies with greater financial resources and broader product portfolios. It must differentiate itself through technological innovation and clinical evidence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, with modest revenue and consistent losses.
Future Projections: Future growth depends on regulatory approvals, successful commercialization of products, and securing additional funding. Analyst projections are not widely available due to the company's size and stage.
Recent Initiatives: Recent initiatives include pursuing regulatory approvals for its devices and expanding clinical trials.
Summary
Nexalin Technology Inc. is a small, early-stage company developing neurostimulation devices for mental health. The company shows some promise with its proprietary technology and non-invasive approach, but faces significant challenges including limited clinical data, competition from larger players, and dependence on regulatory approvals and additional funding. Its future success hinges on securing approvals, demonstrating clinical efficacy, and attracting more investments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexalin Technology Inc.
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-09-16 | President, CEO, CFO & Director Mr. Mark White | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6 | Website https://www.nexalin.com |
Full time employees 6 | Website https://www.nexalin.com | ||
Nexalin Technology, Inc. designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy. It also offers Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. The company was incorporated in 2010 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.